As per the research report, the size of the North America Wound Debridement Products Market is valued at USD 229.06 million in 2023 and is expected to grow at a CAGR of 6.5%, to reach USD 313.83 million by 2028 during the forecast period 2023 to 2028.
Rising incidence of burns and other skin infections such as ulcers and the evolution in wound treatment and management are driving the market for wound debridement products in the North American region. In addition, the increasing incidence of injuries and illnesses in the geriatric population is also driving the market growth.
According to the World Health Organization (WHO) report, it is observed that between 20.5% and 30.8% of older people who fall have moderate to severe injuries, such as bruises, hip fractures, or head trauma in the USA. Likewise, venous insufficiency ulcers made up 52% of chronic leg ulcers among chronic wounds. It has also been reported that the prevalence rate of venous insufficiency-associated ulcers was around 1.70 per 100 people per year in people 65 years of age and older.
The prevalence of ulcers varies between 0.33% and 0.74% per year in the United States, and about 25.6% of these patients may develop foot ulcers in their lifetime. Factors such as high incidence of diabetes with more cases of diabetic foot ulcers, growing per capita healthcare expenditure for chronic ulcers, strong demand for development in better wound debridement products, and favorable government initiatives will benefit North America wound debridement products market in the forecast period.
Manufacturers of wound debridement products focus on developing less expensive products to receive support in higher reimbursements and ease of use for patients in-home care facilities. All these factors mentioned above are anticipated to positively impact the growing industry in the North American region in the upcoming years.
On the contrary, certain factors like the financial recession in research and development, the high cost of superior wound care products, and the lack of adequate reimbursement policies will harm the studied market.
This research report on the North America Wound Debridement Products Market has been segmented and sub-segmented into the following categories:
By Method of Debridement:
By Type of wound:
By Product:
By Country:
The U.S Wound Debridement Products Market is expected to be valued at over USD 252 million by 2027. The growing need to use wound debridement products to treat chronic ulcers is expected to account for the largest share of revenue through 2027.
The growth in this region can be attributed to the increasing prevalence of diabetes, the high penetration of wound debridement products, well-developed medical infrastructure, and the presence of solid players in the region.
According to the National Diabetes Statistics Report, approximately 34.29 million people will have diabetes in 2020. It has increased the incidence of chronic wounds, particularly foot ulcers, resulting in limb amputation. It is also estimated that diabetic patients are ten times more likely to have an amputation at some point in their life. Other leading factors such as expanding product portfolios by key market players, high incidence of chronic disease, and a patient base coupled with demand for advanced wound debridement products will improve the profitability of the market.
On the other hand, revenue from Canada wound debridement products market is projected to show an estimated increase of USD 1.98 million in revenue between 2022 and 2027. The regional market growth can be linked to increasing trends and the high prevalence of chronic diseases that cause chronic, surgical, and traumatic wounds, especially foot ulcers in a diabetic population. In addition, the increasing incidence of burns and favorable reimbursement policies are likely to help the market retain profits in the North American wound debridement products market.
KEY MARKET PLAYERS
Companies playing a dominant role in the North America Wound Debridement Products Market profiled in this report are Coloplast A/S, MediWound Ltd, Derma Sciences, Inc., PuriCore plc and Smith & Nephew Plc, Advanced Medical Solutions Group plc, and Misonix, Inc, ArthroCare Corporation.,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region